Back to results
US 2023/0406955 A1Published application
Antibodies targeting her2 and cd3 and uses thereof
AssigneeJanux Therapeutics, Inc.
InventorsDavid CAMPBELL, Thomas R. DIRAIMONDO,
Life of this patent
Estimating the term…
Abstract
Provided herein are antibodies that selectively bind to HER2 and CD3, pharmaceutical compositions thereof, as well as nucleic acids, and methods for making and discovering the same.
Claims81
An isolated polypeptide complex according to the following formula:
- A-L-B (Formula I)
- wherein
- A comprises a single chain variable fragment (scFv) that binds to CD3;
- B comprises an antigen binding fragment (Fab) or Fab′ that binds to HER2 wherein the Fab or Fab′ comprises a Fab light chain polypeptide comprising a Fab light chain variable domain and a Fab heavy chain polypeptide comprising a Fab heavy chain variable domain comprising complementarity determining region (CDRs):
- HC-CDR1, HC-CDR2, and HC-CDR3, wherein the HC-CDR1, the HC-CDR2, and the HC-CDR3 of the Fab heavy chain variable domain comprise:
- HC-CDR1:
- SEQ ID NO:
- 10;
- HC-CDR2:
- SEQ ID NO:
- 11;
- HC-CDR3:
- SEQ ID NO:
- 12, and wherein the CDRs comprise from 0-2 amino acid modifications in at least one of the HC-CDR1, HC-CDR2, or HC-CDR3;
- and
- L comprises a linker that connects A to B.
13 more elements
An isolated polypeptide complex according to the following formula:
- A-L-D (Formula II)
- wherein
- A comprises a single chain variable fragment (scFv) that binds to CD3;
- D comprises an antigen binding fragment (Fab) or Fab′ that binds to HER2;
- and
- L comprises a linker that connects the C-terminus of A to an N-terminus of D.
3 more elements
Dependencies are inferred from the claim text.